XML 157 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings Per Share
3 Months Ended
Jun. 30, 2013
Earnings Per Share [Abstract]  
Earnings Per Share

15. Earnings Per Share

     The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data):

   Three Months Ended Six Months Ended
   June 30, June 30,
   2013 2012 2013 2012
Numerator for basic and diluted earnings            
 per share - net income (loss) attributable            
 to common stockholders $ (8,508) $ 54,735 $ 46,551 $ 94,037
              
Denominator for basic earnings per             
 share - weighted average shares   273,091   213,498   266,602   206,612
Effect of dilutive securities:            
 Employee stock options   283   261   -   242
 Non-vested restricted shares   370   299   -   290
 Convertible senior unsecured notes   2,737   1,080   -   1,093
Dilutive potential common shares   3,390   1,640   0   1,625
Denominator for diluted earnings per            
 share - adjusted weighted average shares   276,481   215,138   266,602   208,237
              
Basic earnings per share $ (0.03) $ 0.26 $ 0.17 $ 0.46
Diluted earnings per share $ (0.03) $ 0.25 $ 0.17 $ 0.45

The diluted earnings per share calculation for the six months ended June 30, 2013 excludes the dilutive effect of all common stock equivalents as they are anti-dilutive due to the loss from continuing operations attributable to common shareholders. The diluted earnings per share calculations exclude the dilutive effect of 0 and 354,000 common stock equivalents for the three months ended June 30, 2013 and 2012, respectively, and 0 and 366,000 common stock equivalents for the six months ended June 30, 2013 and 2012, respectively, because the exercise prices were higher than the average market price. The Series H Cumulative Convertible and Redeemable Preferred Stock and Series I Cumulative Convertible Perpetual Preferred Stock were not included in the calculations as the effect of conversions into common stock was anti-dilutive.